HALOZYME THERAPEUTICS, INC. Foreign Pre-Tax Income
HALOZYME THERAPEUTICS, INC. (HALO) reported Foreign Pre-Tax Income of -$652.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign · last filed 2026-02-17
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2025 was -$652.00K.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2024 was -$720.00K.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2023 was -$499.00K.
- HALOZYME THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, foreign for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Foreign 12 month |
|---|---|
| 2025-12-31 | -$652.00K 10-K · filed 2026-02-17 |
| 2024-12-31 | -$720.00K 10-K · filed 2026-02-17 |
| 2023-12-31 | -$499.00K 10-K · filed 2026-02-17 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-18 |
| 2021-12-31 | $447.00K 10-K · filed 2024-02-20 |
| 2020-12-31 | -$1.13M 10-K · filed 2023-02-21 |
| 2019-12-31 | -$1.51M 10-K · filed 2022-02-22 |
| 2018-12-31 | -$33.97M 10-K · filed 2021-02-23 |
| 2017-12-31 | -$99.33M 10-K · filed 2020-02-24 |
| 2016-12-31 | -$108.25M 10-K · filed 2019-02-21 |
| 2015-12-31 | -$43.95M 10-K · filed 2018-02-20 |
| 2014-12-31 | -$37.49M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |